The U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for updated labeling of a resorbable implant for anterior cruciate ligament (ACL) repair, indicating a reduced risk of osteoarthritis.
The implant facilitates ACL restoration by stabilizing the blood in the gap between the torn ligament ends. Within eight weeks the implant is resorbed and replaced with fibrovascular repair tissue.
Subscribe to continue reading
- Unlimited access to our content and archive
- Exclusive access to our newsletter
- Join the Conversation! Exclusive access to article comments.
